Ludwig In the News

April 16, 2021

The Ludwig Institute for Cancer Research established a branch at Princeton University that will be wholly dedicated to the study of cancer metabolism and the translation of its findings into new paradigms for cancer prevention and treatment.

April 16, 2021

Ludwig Cancer Research announced on its 50th anniversary the launch of the newest branch based at Princeton University which will be wholly dedicated to the study of cancer metabolism and the translation of its findings into new paradigms for cancer prevention and treatment.

April 13, 2021

Ludwig Cancer Research announces the launch of its newest Branch, based at Princeton University and wholly dedicated to the basic and translational study of cancer metabolism.

February 14, 2021

Linda Bauld, who chairs a session at the upcoming Cancer Prevention – Physical Activity conference convened by Ludwig Cancer Research and Cancer Research UK, spoke on the importance of exercise as a cancer prevention tool.

June 3, 2020

Technology developed in the lab of Ludwig Oxford’s Chunxiao Song that greatly improves the sensitivity, efficiency and ease of sequencing DNA methylation is the basis for the launch of Base Genomics, a new biotechnology company.

April 28, 2020

Clinical study data showed that DETECT-A, Thrive Earlier Detection’s blood test for multiple cancers developed by Ludwig Johns Hopkins researchers, detected ten different cancer types and more than doubled the number of cases detected when combined with traditional screening methods. It also detected several cancers for which there are no standard screening methods.

April 6, 2020

A team led by Sanjiv “Sam” Gambhir, the Virginia and D.K. Ludwig Professor of Cancer Research at Stanford University School of Medicine, has developed a smart toilet that is fitted with technology that can detect a range of disease markers in stool and urine, including those of some cancers, such as colorectal or urologic cancers.

October 3, 2019

Ludwig John Hopkins Co-director Bert Vogelstein sees a future in which everyone has access to an early cancer diagnosis. In this article, he discusses how the company he co-founded, Thrive Earlier Detection, might help achieve that goal.

August 1, 2019

In an open access BMC Medicine article co-authored by Ludwig’s Deputy Scientific Director Bob Strausberg, an international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship between nutrition and cancer. Advancing research on these core areas using a holistic, cross-disciplinary approach could catalyze progress urgently needed to prevent cancer and improve public health globally.

June 18, 2019

Ludwig Johns Hopkins’ Bert Vogelstein and his colleagues have developed several technologies in the past few years that have become the foundations for well-funded spinoff cancer diagnostics companies. For example, CancerSEEK—liquid biopsy tech designed to screen for and detect at least eight different types of cancer at earlier stages—was recently spun out into a startup called Thrive Earlier Detection Corp. (Subscription required)

October 18, 2018

Ludwig Stanford’s Sam Gambhir leads a large study to better understand the transition from normal health to disease as part of Project Baseline, a joint effort between Stanford, Duke and Verily, that could result in the identification of new markers in the blood, stool or urine that help predict cancer and other diseases.

March 21, 2018

A Ludwig Johns Hopkins study published in Science Translational Medicine reports the analysis of an experimental, minimally invasive DNA test for the detection of ovarian and endometrial cancers, both of which are difficult to detect in their early stages, when they are most curable.

March 19, 2018

In a study published in Science Translational Medicine, Ludwig Harvard investigator Rakesh Jain and his colleague Dai Fukumura at Massachusetts General Hospital found that obesity, known to reduce survival in several types of cancer, may also explain the ineffectiveness of angiogenesis inhibitors, which block the formation of blood vessels that feed tumors.

January 19, 2018

In a Science study, Ludwig Johns Hopkins researchers show that their experimental liquid biopsy test found about 70 percent of eight common types of cancer in patients already known to have the disease.

January 1, 2018

Ludwig’s Scientific Director Chi Van Dang, the new Editor-in-Chief of Cancer Research, discusses the evolution of cancer research, advances in areas like the tumor microenvironment, and challenges raised by the complexity of cancer.

December 10, 2017

Ludwig’s Scientific Director Chi Van Dang expressed excitement about promising areas in the Lancet Oncology Commission report, which expands on recommendations of the Cancer Moonshot’s blue ribbon panel.

April 3, 2017

Ludwig Johns Hopkins Co-director Bert Vogelstein illustrated the theme of the 2017 ACCR Annual Meeting—”Discover, Predict, Prevent, Treat”—at this year’s opening plenary. He explained that the development of new therapies goes hand in hand with the development of new prevention strategies. One key step is identifying the source of mutations for each type of cancer by improved molecular markers of disease using diagnostics such as liquid biopsies.

March 23, 2017

A recent study led in part by Ludwig Johns Hopkins Co-director Bert Vogelstein argues that random “mistakes” dividing cells make when copying their DNA account for nearly two-thirds of the mutations that cause cancer. This article, which includes input from Vogelstein, explains the methodology of the study and the implications of its findings.

September 7, 2016

A blue ribbon panel, co-chaired by Tyler Jacks of Ludwig MIT and including Ludwig scientists George Demetri and Levi Garraway, released a report for the Cancer Moonshot that describes a set of 10 recommendations for accelerating cancer research to achieve the ambitious goal of making a decade’s worth of progress in 5 years.

April 20, 2016

U.S. Vice President Joe Biden delivered an address at the AACR Annual Meeting, calling on researchers to accelerate progress against cancer by working more collaboratively and sharing data more freely. Ludwig Harvard director George Demetri was quoted in this article on the address, which also summarized key findings reported at the meeting.

January 15, 2016

Ludwig Harvard director George Demetri talks to MSNBC’s Chris Matthews about what can be accomplished with Vice President Biden’s “Moonshot” initiative.

January 8, 2016

Ludwig Harvard director George Demetri was among the top cancer researchers who met with United States Vice President Joe Biden’s staff to discuss ideas for his cancer “moonshot” initiative announced during President Barack Obama’s State of the Union address.

April 1, 2015

How exactly genes and environment interact to propel malignancy is only just beginning to be worked out, but one thing is clear: our habits play a big role.

October 16, 2014

The National Cancer Institute and other agencies are funding prevention research. But efforts are nowhere near where they ought to be given the approaching tsunami of aging citizens. The bulk of cancer research funding from both public and private sources continues to focus on the treatment of cancer, not its prevention

July 24, 2014

How Daniel K Ludwig’s formula for success has fuelled four decades – and counting – of top-notch cancer research.

April 10, 2014

Government funding, which has long supported the bulk of basic scientific research, is increasingly threatened in the U.S. If we hope to capitalize on the remarkable progress made in molecular medicine over the past few decades to solve such intractable problems as cancer, diabetes, and other diseases, something will have to change—and soon.

March 24, 2014

American science is increasingly starved of funds. In 2013, the U.S. National Institutes of Health was forced to slash $1.5 billion from its budget. As a consequence, only one in seven biomedical researchers who apply for an NIH grant today will receive one — marking an historic low.

January 25, 2014

This month, Daniel Ludwig’s trust made a final US$540 million donation to the six American Ludwig Centers he had helped to found. In total, Ludwig has given over $900 million to the six centres.

January 9, 2014

In the case of these six cancer research centers, a $540 million endowment is meant to help them pursue work that is speculative and risky, unencumbered by the profit requirements of “the market” or the conservatism and restrictions of government funding.

January 7, 2014

Six U.S. medical centers will each receive $90 million to pursue cancer research with very few strings attached.

January 6, 2014

Six facilities for cancer studies launched in 2006 by New York-based charity Ludwig Cancer Research will each receive $90-million more from the parent group to pursue unrestricted research into how the disease starts, spreads, and can be stopped.

January 6, 2014

The estate of the late American shipping magnate Daniel Ludwig on Monday donated a total of $540 million to six elite U.S. cancer research facilities, making one of the largest one-time gifts dedicated to combating the disease.

January 6, 2014

An American shipping magnate’s trust will announce on Monday one of the largest philanthropic gifts to support cancer research: more than half a billion dollars to be divided equally among six institutions, including Harvard Medical School and the Massachusetts Institute of Technology.

January 6, 2014

Stanford has received a vast sum of money to study a tiny population of deadly cancer cells, a gift that could help combat the heartbreak of phoenixlike disease recurrence.

January 6, 2014

Gift from Ludwig Cancer Research fund comes as government, private grants have declined.

January 6, 2014

The Ludwig Cancer Research organization announces one of the largest gifts ever toward cancer research with $540 million to six research centers across the country.

January 6, 2014

Johns Hopkins University scientists will share in one of the largest one-time philanthropic gifts for cancer research ever made, $540 million aimed at preventing and curing the disease, officials are scheduled to announce today.

January 6, 2014

MIT and Harvard each received $90 million from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, which will provide funding to transform basic research on metastasis, the process by which cancer cells spread from a primary tumor to distant sites in the body.

January 6, 2014

A trust fund created by billionaire shipping tycoon Daniel K. Ludwig ends today with a bang and a gift to research. Six U.S. medical centers will receive $540 million—$90 million each—from the fund to endow cancer studies in perpetuity.

Notice
?

You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?

Continue
Cancel